

Post-traumatic stress disorders - Pipeline Insight, 2021

<https://marketpublishers.com/r/P9D591E6A7AEN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P9D591E6A7AEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Post-traumatic stress disorders - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Post-traumatic stress disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Post-traumatic stress disorders Understanding

Post-traumatic stress disorders: Overview

Post-traumatic stress disorder (PTSD) is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape or who have been threatened with death, sexual violence or serious injury. PTSD affects approximately 3.5 percent of U.S. adults every year, and an estimated one in 11 people will be diagnosed with PTSD in their lifetime. Women are twice as likely as men to have PTSD.

Symptoms of PTSD fall into four categories. Specific symptoms can vary in severity.

Intrusion, Avoidance, Alterations in cognition and mood, Alterations in arousal and reactivity. A diagnosis of PTSD requires exposure to an upsetting traumatic event. However, the exposure could be indirect rather than first hand. Treatment usually involves psychotherapy and counseling, medication, or a combination. Options for psychotherapy will be specially tailored for managing trauma. They include: Cognitive processing therapy (CPT), Exposure therapy. Some medications can be used to treat the symptoms of PTSD. Selective serotonin reuptake inhibitors (SSRIs), such as paroxetine, are commonly used. SSRIs also help treat depression, anxiety and sleep problems, symptoms that are often linked to PTSD.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Post-traumatic stress disorders R&D. The therapies under development are focused on novel approaches for Post-traumatic stress disorders.

Post-traumatic stress disorders Emerging Drugs Chapters

This segment of the Post-traumatic stress disorders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Post-traumatic stress disorders Emerging Drugs

TNX-102 SL: Tonix Pharmaceuticals

TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug which acts as antagonists of Alpha 1 adrenergic receptor, Histamine H1 receptor and Serotonin 2A receptor.

It is currently in Phase III stage of development for Post-traumatic stress disorders and is being developed by Tonix Pharmaceuticals.

NYX-783: Aptinyx

NYX-783 is a novel, oral small molecule NMDA receptor modulator in development for the treatment of post-traumatic stress disorder, or PTSD. Dysregulation of NMDA receptor-mediated processes may underlie the development and / or persistence of PTSD.

It is currently in Phase II stage of development for Post-traumatic stress disorders and is being developed by Aptinyx

Further product details are provided in the report..

Post-traumatic stress disorders: Therapeutic Assessment

This segment of the report provides insights about the different Post-traumatic stress disorders drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Post-traumatic stress disorders

There are approx. 15+ key companies which are developing the Post-traumatic stress disorders. The companies which have their Post-traumatic stress disorders drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Post-traumatic stress disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Post-traumatic stress disorders: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Post-traumatic stress disorders therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-traumatic stress disorders drugs.

Post-traumatic stress disorders Report Insights

Post-traumatic stress disorders Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Post-traumatic stress disorders Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Post-traumatic stress disorders drugs?

How many Post-traumatic stress disorders drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Post-traumatic stress disorders?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Post-traumatic stress disorders therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Post-traumatic stress disorders and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tonix Pharmaceuticals

Nobilis Therapeutics

Bionorica

H. Lundbeck A/S

Bionomics

Jazz Pharmaceuticals

Chronos Therapeutic

PSY Therapeutics

VistaGen Therapeutics

Aptiny

Alzamend

Key Products

TNX-102 SL

TNX-601

TNX-1600

NBTX-001

BX-1

Lu AG06466

BNC210

JZP-150

PSY-05

PH94B

NYX-783

AL001

Contents

- Introduction
- Executive Summary
- Post-traumatic stress disorders: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Post-traumatic stress disorders– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Post-traumatic stress disorders companies’ collaborations, Licensing, Acquisition
 - Deal Value Trends
- Post-traumatic stress disorders Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- TNX-102 SL: Tonix Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report..
- Mid Stage Products (Phase II)
 - Comparative Analysis
- NYX-783: Aptinyx
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report..
- Early Stage Products (Phase I)
 - Comparative Analysis

Lu AG06466: H. Lundbeck A/S

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical and Discovery Stage Products

Comparative Analysis

TNX-1600: Tonix Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Post-traumatic stress disorders Key Companies

Post-traumatic stress disorders Key Products

Post-traumatic stress disorders- Unmet Needs

Post-traumatic stress disorders- Market Drivers and Barriers

Post-traumatic stress disorders- Future Perspectives and Conclusion

Post-traumatic stress disorders Analyst Views

Post-traumatic stress disorders Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Post-traumatic stress disorders

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Post-traumatic stress disorders

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Post-traumatic stress disorders - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P9D591E6A7AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9D591E6A7AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970